Login
Companies $CADL
$5.85 +$0.04 (0.69%) After hours
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc.

candeltx.com

What Do They Do?

Develops off-the-shelf virus-based treatment candidates for patients with cancer, including people with solid tumors.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −94% (Loss)
vs −$11.3M in Q3 FY2025

Who Do They Compete With?

Competes with AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Merck &, Novartis, Pfizer, Genentech, Johnson & Johnson, Replimune Group, Amgen, Astellas Pharma, Istari Oncology, Orca Therapeutics, CG Oncology, ImmVira, IconOVir Bio, and FerGene

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support